Matinas BioPharma Holdings Inc (MTNB) — Cash Flow-to-Debt Ratio
Matinas BioPharma Holdings Inc (MTNB) has a Cash Flow-to-Debt Ratio of -0.56x as of March 2026, meaning its operating cash flow of $-1.60 Million could theoretically repay -1% of its total liabilities ($2.85 Million) in one year. See Matinas BioPharma Holdings Inc (MTNB) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Matinas BioPharma Holdings Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Matinas BioPharma Holdings Inc across 14 annual periods. Also explore MTNB shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Matinas BioPharma Holdings Inc (2012–2025)
Year-by-year debt coverage analysis for Matinas BioPharma Holdings Inc. For market capitalisation and broader financial context, see Matinas BioPharma Holdings Inc (MTNB) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.95x | $-7.01 Million | $2.38 Million | ▲ +6.3% |
| 2024 | -3.14x | $-15.88 Million | $5.05 Million | ▼ -20.6% |
| 2023 | -2.61x | $-15.28 Million | $5.86 Million | ▼ -474.9% |
| 2022 | -0.45x | $-19.16 Million | $42.23 Million | ▲ +73.7% |
| 2021 | -1.72x | $-15.22 Million | $8.83 Million | ▲ +28.2% |
| 2020 | -2.40x | $-17.37 Million | $7.24 Million | ▼ -22.4% |
| 2019 | -1.96x | $-14.09 Million | $7.19 Million | ▲ +27.8% |
| 2018 | -2.72x | $-10.32 Million | $3.80 Million | ▲ +11.3% |
| 2017 | -3.06x | $-11.46 Million | $3.74 Million | ▼ -33.5% |
| 2016 | -2.29x | $-6.12 Million | $2.67 Million | ▲ +31.5% |
| 2015 | -3.35x | $-7.81 Million | $2.33 Million | ▲ +52.3% |
| 2014 | -7.02x | $-7.96 Million | $1.13 Million | ▼ -101.9% |
| 2013 | -3.48x | $-2.99 Million | $858.97K | ▼ -412.8% |
| 2012 | -0.68x | $-57.26K | $84.43K | — |